With the discovery of specific activating gene alterations (e.g., EGFR), preclinical development and the clinical validation of respective targetable therapeutics for oncogene-driven NSCLC has led to the approval of new targeted therapies [56,60,61,62,63,64,65]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.